NEMO-Binding Domain Binding Peptide, Cell-Permeable

Name: NEMO-Binding Domain Binding Peptide, Cell-Permeable
Brand: MM

A cell-permeable Antennapedia-NBD (wild type) fusion peptide that exhibits anti-inflammatory properties.

Synonym(s):

NEMO-Binding Domain Binding Peptide, Cell-Permeable, DRQIKIWFQNRRMKWKKTALDWSWLQTE, NBD-Binding Peptide, Cell Permeable

Sign Into View Organizational & Contract Pricing

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₇₀H₂₅₉N₄₉O₄₂S

Molecular Weight:

3693.24

UNSPSC Code:

41116107

Quality Level

100

Assay

≥95% (HPLC)

form

lyophilized solid

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze
desiccated (hygroscopic)

color

white

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

−20°C

General description

A cell-permeable Antennapedia-NBD (NEMO binding domain) (wild type) fusion peptide that exhibits anti-inflammatory activity in mouse model of acute inflammation. NBD is an amino terminal α-helical region of the NEMO (NF-κB essential modifier; IKKγ) associated with a carboxyl-terminal segment of IKKα and IKKβ. This peptide blocks the association of NEMO with the IKK complex and prevents NF-κB activation. NEMO is also reported to suppress the intrinsic basal activity of the IKK complex. Its anti-inflammatory properties are attributed to the inhibition of cytokine-induced NF-κB activation and NF-κB-dependent gene expression. Does neither affect the TNF-α-induced phosphorylation of c-Jun nor the DNA binding of Oct-1 transcription factor.

A cell-permeable Antennapedia-NBD (wild type) fusion peptide that exhibits anti-inflammatory properties. Acts by inhibiting cytokine-induced NF-κB activation and NF-κB-dependent gene expression. Suggested to block the interaction of NEMO with the IKK (IκB)-kinase complex and thereby prevents NF-κB activation. Does not affect the TNF-α-induced phosphorylation of c-Jun and DNA binding of the transcription factor Oct-1.

Biochem/physiol Actions

Cell permeable: yes

Primary Target
cytokine-induced NF-κB activation and NF-κB-dependent gene expression

Product does not compete with ATP.

Reversible: no

Packaging

Packaged under inert gas

Physical form

Supplied as a trifluoroacetate salt.

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

H-Asp-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu-OH

Jimi, E., et al. 2004. Nat. Med., 10, 617.
Siegmund, D., et al. 2001. J. Biol. Chem.276, 43708.
May, M.J., et al. 2000. Science289, 1550.
Li, Q., et al. 1999. Science284, 321.

Note: This peptide will precipitate when added to tissue culture medium even at 100 µM concentrations. However, sufficient material will stay in the medium to permeate cells.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Renal proximal tubular NEMO plays a critical role in ischemic acute kidney injury.

Sang Jun Han et al.

JCI insight, 5(19) (2020-09-18)

We determined that renal proximal tubular (PT) NF-κB essential modulator (NEMO) plays a direct and critical role in ischemic acute kidney injury (AKI) using mice lacking renal PT NEMO and by targeted renal PT NEMO inhibition with mesoscale nanoparticle-encapsulated NEMO

Microphthalmia transcription factor expression contributes to bone marrow failure in Fanconi anemia.

Alessia Oppezzo et al.

The Journal of clinical investigation, 130(3), 1377-1391 (2019-12-27)

Hematopoietic stem cell (HSC) attrition is considered the key event underlying progressive BM failure (BMF) in Fanconi anemia (FA), the most frequent inherited BMF disorder in humans. However, despite major advances, how the cellular, biochemical, and molecular alterations reported in